Purpose Differences in cellular levels of histone modifications have predicted clinical
outcome in certain cancers. Here, we studied the prognostic and predictive value of three …

Polycomb repressive complex 2 (PRC2) and its core member enhancer of zeste homolog 2
(EZH2) mediate the epigenetic gene silencing mark: trimethylation of lysine 27 on histone 3 …

The best-understood mechanism by which EZH2 exerts its oncogenic function is through
polycomb repressive complex 2 (PRC2)-mediated gene repression, which requires its …

The role of enhancer of zeste homolog 2 (EZH2) in cancer is complex and may vary
depending on the cellular context. We found that EZH2 is aberrantly overexpressed in the …

Background: Epigenetic alterations are common in prostate cancer, yet how these
modifications contribute to carcinogenesis is poorly understood. We investigated whether …

Purpose: Enhancer of zeste homologue 2 (EZH2), a histone methyltransferase, plays a key
role in transcriptional repression through chromatin remodeling. Our objectives were to …

Malignant peripheral nerve sheath tumors (MPNST) are aggressive sarcomas typically
developing in the context of neurofibromatosis type 1 (NF-1). With the exception of surgical …

Background To improve the prognosis of patients with pancreatic cancer, new biomarkers
are required for earlier, pre-symptomatic diagnosis. Epigenetic mutations take place at the …

Motivation: Eukaryotic gene expression (GE) is subjected to precisely coordinated multi-
layer controls, across the levels of epigenetic, transcriptional and post-transcriptional …

Traditionally the stratification of many cancers involves combining tumour and
clinicopathological features (eg, patient age; tumour size, grade, receptor status and …